Eos BioInnovation is an investment firm focused on launching and building start-ups in the field of regenerative medicine. The company specializes in incubating, launching, and developing early-stage companies that emerge from leading academic labs and research institutions. By supporting these ventures, Eos BioInnovation aims to transform innovation in regenerative medicine and enable clients to achieve a strong track record of success.
Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.
HDAX Therapeutics
Seed Round in 2024
HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.